Shopping Cart
Remove All
Your shopping cart is currently empty
Pavurutamab (AMG-701) is a bispecific T-cell engager targeting CD3 and B-cell maturation antigens (BCMA), with an extended half-life derived from Pacanalotamab. Its Fc region is engineered for improved pharmacokinetics, offering potential in immune regulation and treatment of multiple myeloma (MM) [1] [2] [3] [4].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $622 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $1,580 | 2-4 weeks | 2-4 weeks |
| Description | Pavurutamab (AMG-701) is a bispecific T-cell engager targeting CD3 and B-cell maturation antigens (BCMA), with an extended half-life derived from Pacanalotamab. Its Fc region is engineered for improved pharmacokinetics, offering potential in immune regulation and treatment of multiple myeloma (MM) [1] [2] [3] [4]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Cas No. | 2250292-39-6 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.